These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 11149939)

  • 41. Two new proteases in the MHC class I processing pathway.
    Stoltze L; Schirle M; Schwarz G; Schröter C; Thompson MW; Hersh LB; Kalbacher H; Stevanovic S; Rammensee HG; Schild H
    Nat Immunol; 2000 Nov; 1(5):413-8. PubMed ID: 11062501
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Development of the proteasome inhibitor Velcade (Bortezomib).
    Adams J; Kauffman M
    Cancer Invest; 2004; 22(2):304-11. PubMed ID: 15199612
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Proteasome inhibition: a novel approach to cancer therapy.
    Adams J
    Trends Mol Med; 2002; 8(4 Suppl):S49-54. PubMed ID: 11927288
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The requirement for proteasome activity class I major histocompatibility complex antigen presentation is dictated by the length of preprocessed antigen.
    Yang B; Hahn YS; Hahn CS; Braciale TJ
    J Exp Med; 1996 Apr; 183(4):1545-52. PubMed ID: 8666912
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Potential for proteasome inhibition in the treatment of cancer.
    Adams J
    Drug Discov Today; 2003 Apr; 8(7):307-15. PubMed ID: 12654543
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells.
    Chauhan D; Li G; Shringarpure R; Podar K; Ohtake Y; Hideshima T; Anderson KC
    Cancer Res; 2003 Oct; 63(19):6174-7. PubMed ID: 14559800
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Apoptosis induction resulting from proteasome inhibition.
    Shinohara K; Tomioka M; Nakano H; Toné S; Ito H; Kawashima S
    Biochem J; 1996 Jul; 317 ( Pt 2)(Pt 2):385-8. PubMed ID: 8713062
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A major role for TPPII in trimming proteasomal degradation products for MHC class I antigen presentation.
    Reits E; Neijssen J; Herberts C; Benckhuijsen W; Janssen L; Drijfhout JW; Neefjes J
    Immunity; 2004 Apr; 20(4):495-506. PubMed ID: 15084277
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Glutathiolation of the proteasome is enhanced by proteolytic inhibitors.
    Demasi M; Shringarpure R; Davies KJ
    Arch Biochem Biophys; 2001 May; 389(2):254-63. PubMed ID: 11339815
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Proteasome inhibitors as new anticancer drugs.
    Adams J
    Curr Opin Oncol; 2002 Nov; 14(6):628-34. PubMed ID: 12409653
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Inhibition of bone resorption by inhibitors of tripeptidyl peptidase-I.
    Vines D; Warburton MJ
    Biochem Soc Trans; 1997 Nov; 25(4):S615. PubMed ID: 9450043
    [No Abstract]   [Full Text] [Related]  

  • 52. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB.
    Russo SM; Tepper JE; Baldwin AS; Liu R; Adams J; Elliott P; Cusack JC
    Int J Radiat Oncol Biol Phys; 2001 May; 50(1):183-93. PubMed ID: 11316563
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Semi-high throughput method of measuring proteasome inhibition in vitro and in cultured cells.
    Keyomarsi K; Efuet ET; Bui TN
    Cell Biol Toxicol; 2011 Apr; 27(2):123-31. PubMed ID: 20853140
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Peptidyl aldehyde inhibitors of proteasome induce apoptosis rapidly in mouse lymphoma RVC cells.
    Tanimoto Y; Onishi Y; Hashimoto S; Kizaki H
    J Biochem; 1997 Mar; 121(3):542-9. PubMed ID: 9133624
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Presentation of a new H-2D(k)-restricted epitope in the Tax protein of human T-lymphotropic virus type I is enhanced by the proteasome inhibitor lactacystin.
    Lomas M; Hanon E; Tanaka Y; Bangham CRM; Gould KG
    J Gen Virol; 2002 Mar; 83(Pt 3):641-650. PubMed ID: 11842259
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Proteasome inhibitors alter levels of intracellular peptides in HEK293T and SH-SY5Y cells.
    Dasgupta S; Castro LM; Dulman R; Yang C; Schmidt M; Ferro ES; Fricker LD
    PLoS One; 2014; 9(7):e103604. PubMed ID: 25079948
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines.
    Ling YH; Liebes L; Jiang JD; Holland JF; Elliott PJ; Adams J; Muggia FM; Perez-Soler R
    Clin Cancer Res; 2003 Mar; 9(3):1145-54. PubMed ID: 12631620
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The effect of the proteasome inhibitor lactacystin on the presentation of transporter associated with antigen processing (TAP)-dependent and TAP-independent peptide epitopes by class I molecules.
    Bai A; Forman J
    J Immunol; 1997 Sep; 159(5):2139-46. PubMed ID: 9278300
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pathways accessory to proteasomal proteolysis are less efficient in major histocompatibility complex class I antigen production.
    Kessler B; Hong X; Petrovic J; Borodovsky A; Dantuma NP; Bogyo M; Overkleeft HS; Ploegh H; Glas R
    J Biol Chem; 2003 Mar; 278(12):10013-21. PubMed ID: 12488316
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Proteasome inhibitors].
    Hatake K; Mishima Y; Terui Y
    Gan To Kagaku Ryoho; 2004 Jul; 31(7):999-1002. PubMed ID: 15272575
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.